Phase 2 N=6 Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change in Pulmonary Vascular Resistance (PVR) at Three Months — -0.49 Wood units — p=0.09
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 3D Rotational CT Angiogram With Embolization Guidance and CBCT in Prostatic Artery Embolization
Enlarged Prostate
Primary: Time for Prostatic Artery Catheterization — 273.40; 181.71; 206.38; 155.96 seconds
N/A N=33 The Effect of OrthoPulse™ on the Rate of Orthodontic Tooth Movement
Malocclusion
Primary: Evaluation of Whether OrthoPulse Use Affects the Rate of Orthodontic Tooth Movement During Full Mouth Fixed Orthodontic Treatment — 1.09; .39 millimeters per week
Phase 2 N=141 A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Change From Baseline to Week 4 in Hamilton Rating Scale for Depression (HAM-D17) Total Score — -7.1; -9.3; -6.6; -1.5 score on a scale — p=0.014
N/A N=197 Prospective Study on Embolization of Intracranial Aneurysms With Pipeline™ Embolization Device
Intracranial Aneurysm
Primary: The Percentage of Participants With the Occurrence of Major Stroke in the Territory Supplied by the Treated Artery or Neurological Death at 12-Months Post Procedure…
Phase 3 N=437 A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
Depressive Disorder, Treatment-Resistant
Primary: Time to Relapse in Participants With Stable Remission (Maintenance Phase) — NA; 273.0 Days — p== 0.003
Phase 2 N=49 Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
Prostate Cancer
Primary: Fold Change in Serum N-telopeptides From Baseline — 0.85; 1.34 fold change
Phase 2 N=26 Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)
Microvascular Angina
Primary: Change in Seattle Angina Questionnaire Score Regarding Angina Frequency — 0.70; 0.27 score on a scale
Phase 3 N=20 Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Number of Participants With at Least One Adverse Event (AE) — 15 Participants
Phase 2 N=37 Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma
Asthma
Primary: FEV1 Standardized Area Under the Curve (AUC 0-24h) After Last Evening Dose of 14-day Treatment Period — 3.4305; 3.4361; 2.8209 Liters
Phase 4 N=81 Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
Pregnancy
Primary: Percentage of Participants With Injection-site Reactions Post Tdap and IIV4 Administration — 47.5; 48.6; 37.5; 45.9 percentage of participants
Phase 2 N=66 PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib
Carcinoma, Non Small Cell Lung
Primary: Best Overall Response (BOR) in Participants With Adenocarcinoma Histology — 0; 2; 28; 12 Participants
N/A N=9 Daily Weight Feedback for Wheelchair Users to Promote Weight Loss
Overweight and Obesity · Depression
Primary: Weight Change — 196.0; 192.8 pounds
Phase 2 N=101 AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock
Traumatic Shock
Primary: Number of Blood Products Transfused — 1.7; 3.0 Litre
Phase 2 N=200 Study of Orofacial Pain and PropRANOlol
Temporomandibular Disorders
Primary: Change in the Weekly Mean Pain Index After 9 Weeks of Treatment — -13.9; -12.1 units on a scale — p=0.414